Mavacamten + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HOCM, Hypertrophic Obstructive Cardiomyopathy
Conditions
HOCM, Hypertrophic Obstructive Cardiomyopathy
Trial Timeline
Jul 6, 2020 → May 20, 2024
NCT ID
NCT04349072About Mavacamten + Placebo
Mavacamten + Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for HOCM, Hypertrophic Obstructive Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04349072. Target conditions include HOCM, Hypertrophic Obstructive Cardiomyopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06253221 | Phase 3 | Active |
| NCT04349072 | Phase 3 | Completed |